Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:DICE

DICE Therapeutics (DICE) Stock Price, News & Analysis

DICE Therapeutics logo

About DICE Therapeutics Stock (NASDAQ:DICE)

Key Stats

Today's Range
$47.55
$47.55
50-Day Range
$46.62
$47.55
52-Week Range
$15.08
$47.90
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Stock News Headlines

The most serious warning of my career
With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.
See More Headlines

DICE Stock Analysis - Frequently Asked Questions

DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77.

DICE Therapeutics (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that DICE Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Honeywell International (HON), HubSpot (HUBS), Walt Disney (DIS) and Bank of America (BAC).

Company Calendar

Last Earnings
11/12/2021
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DICE
Fax
N/A
Employees
71
Year Founded
N/A

Profitability

Net Income
$-83,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.13 million
Book Value
$10.86 per share

Miscellaneous

Free Float
45,392,000
Market Cap
$2.27 billion
Optionable
Not Optionable
Beta
1.03
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:DICE) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners